<!DOCTYPE html>
<html>
<head>
<link href="https://fonts.googleapis.com/css2?family=Oxanium&display=swap" rel="stylesheet">
<style>

body {
    font-family: 'Oxanium', cursive;
}

span {color:#f8df92;}
p {color:red;font-family:'Oxanium', cursive;}

.main {
  width: 100%;
  height: 100%;
  overflow-y: scroll; /* Add the ability to scroll */
}

/* Hide scrollbar for Chrome, Safari and Opera */
.main::-webkit-scrollbar {
    display: none;
}

/* Hide scrollbar for IE, Edge and Firefox */
.main {
  -ms-overflow-style: none;  /* IE and Edge */
  scrollbar-width: none;  /* Firefox */
}

.content {
  width: auto;
  height: 365px;
  font-size:7pt;
  font-family:'Oxanium', cursive;
  color:#f8df92;
  background-color:transparent;
  line-height:1.38;
  margin-top:0pt;
  margin-bottom:0pt;
  padding-right:5pt;
  /* border-right: 2px solid rgba(255, 233, 185, 0.5); */
  overflow-y: scroll; /* Add the ability to scroll */
}

.author {
  font-weight:700;
  font-style:normal;
  font-variant:normal;
  // text-decoration:underline;
  -webkit-text-decoration-skip:none;
  text-decoration-skip-ink:none;
  vertical-align:baseline;
  white-space:pre;
  white-space:pre-wrap;"
}

.article {
  font-weight:400;
  font-style:normal;
  font-variant:normal;
  text-decoration:none;
  vertical-align:baseline;
  white-space:pre;
  white-space:pre-wrap;
}

/* width */
::-webkit-scrollbar {
  width: 2px;
}

/* Track */
::-webkit-scrollbar-track {
  border-radius: 0px;
}
 
/* Handle */
::-webkit-scrollbar-thumb {
  background: #f8df92; 
  border-radius: 0px;
}

/* Handle on hover */
::-webkit-scrollbar-thumb:hover {
  background: #f8df92; 
}

</style>
</head>
<body>

<div class="content">
	<p>
		<a target="_blank" style="text-decoration:none;">
			<span class="author">Indications</span>
			<span class="article"></span>
		</a>
	</p>
	<p>
		<a target="_blank" style="text-decoration:none;">
			<span class="author"></span>
			<span class="article">VABYSMO (faricimab-svoa) is a prescription medicine given by injection into the eye, used to treat adults with Neovascular (Wet) Age‑related Macular Degeneration (AMD) and Diabetic Macular Edema (DME). </span>
		</a>
	</p>
</div>
<div class="main">
	<p style="line-height:1.38;margin-top:0pt;margin-bottom:0pt;color:#f8df92;">
		<span style="font-size:15pt;font-weight:700;font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline;white-space:pre;white-space:pre-wrap;">IMPORTANT SAFETY INFORMATION</span>
	</p>	
</div>
<div class="content">
	<p>
		<a target="_blank" style="text-decoration:none;">
			<span class="author">Contraindications</span>
			<span class="article"></span>
		</a>
	</p>
	<p>
		<a target="_blank" style="text-decoration:none;">
			<span class="author"></span>
			<span class="article">VABYSMO is contraindicated in patients who have an infection in or around their eye, have active swelling around their eye that may include pain and redness, or are allergic to VABYSMO or any of the ingredients in VABYSMO. </span>
		</a>
	</p>
	<p>
		<a target="_blank" style="text-decoration:none;">
			<span class="author">Warnings and Precautions</span>

				<ul style="margin-top:0; padding-top:0;">
					<li>Injections like the one for VABYSMO can cause an eye infection (endophthalmitis) or separation of layers of the retina (retinal detachment). Patients should seek medical care if they experience increasing eye pain, vision loss, sensitivity to light, or redness in the white of the eye. </li>
					<li>VABYSMO may cause a temporary increase in pressure in the eye (intraocular pressure), which occurs 60 minutes after the injection. </li>
					<li>Although not common, VABYSMO patients have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes (thromboembolic events). In clinical studies for wet AMD during the first year, 7 out of 664 patients treated with VABYSMO reported such an event. In DME studies during the first year, 25 out of 1,262 patients treated with VABYSMO reported such an event. </li>
				</ul>

		</a>
	</p>
	<p>
		<a target="_blank" style="text-decoration:none;">
			<span class="author">Adverse Reactions</span>
			<span class="article"></span>
		</a>
	</p>
	<p>
		<a target="_blank" style="text-decoration:none;">
			<span class="author"></span>
			<span class="article">The most common adverse reaction (≥5%) reported in patients receiving VABYSMO was blood on the white of the eye (conjunctival hemorrhage, 7%). These are not all the possible side effects of VABYSMO. </span>
		</a>
	</p>
	<p>
		<a target="_blank" style="text-decoration:none;">
			<span class="author">Pregnancy, Lactation, Females and Males of Reproductive Potential</span>

				<ul style="margin-top:0; padding-top:0;">
					<li>Based on how VABYSMO interacts with your body, there may be a potential risk to an unborn baby. Patients should use birth control before their first injection, during their treatment with VABYSMO, and for 3 months after their last dose of VABYSMO. </li>
					<li>It is not known if VABYSMO passes into breast milk. Patients should talk to their healthcare provider about the best way to feed their baby if they receive VABYSMO. </li>
				</ul>

		</a>
	</p>	
	<p>
		<a href="https://www.fda.gov/medwatch" target="_blank" style="text-decoration:none;">
			<span class="author"></span>
			<span class="article">Side effects may be reported to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. They may also report side effects to Genentech at (888) 835-2555.</span>
		</a>
	</p>
	<p>
		<a href="https://www.gene.com/download/pdf/vabysmo_prescribing.pdf" target="_blank" style="text-decoration:none;">
			<span class="author"></span>
			<span class="article">Please see additional Important Safety Information in the full VABYSMO Prescribing Information.</span>
		</a>
	</p>

</div>
</body>
</html>